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HBS Ag seroclearance and seroconversion time in Patients 
with chronic hepatitis B Infection 
 
Abstract 
Background: Hepatitis B Surface antigen (HBsAg) seroclearance and seroconversion 
(development of antibodies against HBsAg) can increases the survival of Chronic hepatitis 
B (CHB) patients. The aim of this study was to determine the percentage and timing of 
HBsAg seroclearance and seroconversion in patients with chronic hepatitis B infection. 
Methods: 1026 patients with CHB infection who referred to a private clinic were included. 
These patients had been followed-up for an average of 15 years. The patients whose HBs 
Ag was cleared from the blood and remained negative until the end of follow-up were 
designated as HBs Ag serocleared and the patients whose HBs Ab was positive during 
follow-upwas designated as HBs Ag seroconverted. The time of seroclearance and 
seroconversion of patients was recorded. Liver function tests, alpha-fetoprotein (AFP) and 
Hepatitis B early antigen (HBe Ag) status were extracted from the patients’ medical 
records. Data were analysis with SPSS 17. 
Results: The duration of follow-up was from 2 to 410 months and most patients were 
males (58.2%). 
The survival rate of HBs Ag positivity after 5, 10 and 15 years were 95.6, 89.4 and 80.7%, 
and 98, 93.5 and 84.9% of patients had not yet developed anti-HBs antibodies after 5, 10 
and 15 years, respectively. Age, gender and taking medication had no effect on HBs Ag 
clearance from the blood or anti-HBs production 
Conclusion: The HBs Ag seroconversion is a rare occurrence, but the incidence of this 
may increase with time, age and drug consumption. Though there was no relationship in 
our patients  
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Hepatitis B infection is a viral disease affecting a large population worldwide and a 
major global health problem because of its important role in human mortality (1, 2). It is 
one of the main causes of cirrhosis and hepatocellular carcinoma (HCC) and as an 
important cause of death in patients (3, 4). Due to the interaction between virus and host, 
hepatitis B virus infection presents itself in a variety of clinical manifestations including 
acute hepatitis chronic hepatitis hepatic cirrhosis, , and HCC (5). In acute hepatitis, an 
adequate and timely immune response can lead to the clearance of the virus, resulting from 
the activity of different types of T cells. However a deficient T cell response can lead to 
chronic viral infection and progression to cirrhosis and HCC. Several studies have shown 
that different phases of the disease are caused by the virus and altered host immune 
response.  
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Interaction between the virus, liver cells, immune system 
and antiviral therapy sometimes causes the virus gene to 
mutate, leading to the virus escaping from the immune 
system and drug resistance (6-8). In the normal course of 
chronic hepatitis B infection, hepatitis B surface antigens 
(HBs Ag) may be cleared from the patient's blood. In this 
phase of the disease, antibodies to the hepatitis B core 
antigen (HBcAg) are found in the blood, and antibody 
against HBsAg (Anti-HBs) may or may not be found. HBs 
Ag clearance can prevent progression of disease to cirrhosis 
or HCC and increase the survival of affected patients. (6, 9, 
10). HBs Ag seroclearance is a rare event in chronic hepatitis 
B. The incidence of HBs Ag seroclearance in patients 
affected with chronic hepatitis early in life is estimated to be 
about 0.1 to 0.8% per year, and be 0.4-2% in patients 
affected in adulthood. Although it is believed that HBs Ag 
seroclearance in patients with chronic hepatitis B is a good 
sign of inprogression to HCC, the patients may develop 
cirrhosis and HCC despite HBs Ag clearance from blood (4, 
9). Several studies have indicated that HBs Ag seroclearance 
can be a sign of effective treatment for patients with hepatitis 
B infection (4, 11-13). Despite this fact the spontaneous 
clearance of HBs Ag in untreated patients is rare, it may 
occur in the normal course of the disease (4). Factors such as 
age, gender, drug consumption and virus DNA level are 
effective at the time of seroclearance and seroconversion 
(14). Therefore, the aim of this study was to determine the 
percentage and timing of HBs Ag seroclearance and HBs Ag 
seroconversion in 1026 patients with chronic hepatitis B, 
followed-up for an average of 15 years and investigate some 
of its contributing factors. 
 
 
Methods 
In a historical cohort study, from 2004 to 2019 in Babol, 
1026 patients who referred to a private clinic with positive 
HBs Ag for 6 months were included. The data was extracted 
from the patients’ medical records. These patients had been 
followed-up for an average of 15 years. The HBs Ag, HBs 
Ab, liver enzymes and alpha-fetoprotein (AFP) HBeAg of 
patients were measured every 6 months. 
The patients whose HBs Ag was cleared from the blood and 
remained negative until the end of follow-up were 
designated as HBs Ag serocleared and the patients whose 
HBs Ab was positive during follow-up was designated as 
HBs Ag seroconverted. The HBs Ab>10 was considered as 
positive. The time of seroclearance and seroconversion of 
patients and also the last alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) was recorded. The range 
for normal AST and ALT are considered 5 to 50 units per 
liter. Patients with concomitant hepatitis C, hepatitis D, 
cirrhosis or HCC were excluded from the current study.  
Statistical analysis: Data were analyzed using SPSS 17. 
Descriptive data were reported in frequency, mean and standard 
deviation. The Kaplan-Meier method and Cox regression 
model were used for survival analysis. Crude and adjusted 
hazard ratios (HR) with 95% confidence intervals (CI) were 
reported, and p<0.05 was considered as significant level. 
 
 
Results 
 Totally, 1026 HBs Ag
+
 patients whose HBs Ag remained 
positive for at least 6 months were retrospectively reviewed. 
The demographic characteristics of these patients are 
summarized in table 1. 
 
Table 1. Baseline characteristics of chronic hepatitis B 
patients 
Characteristics  
Age of initial visit (mean±SD) 30.82±11.27 
Sex, N (%) 
         Male 
         female 
 
597 (58.2) 
429 (41.8) 
Drug consumption, N (%) 
        Yes 
         No  
 
38 (3.7) 
988 (96.3) 
Age (Year), N (%)  
       <30 
       ≥30 
 
594 (57.9) 
432 (42.1) 
Liver Function Tests (Mean±SD) (IU/L) 
        ALT 
        AST 
 
33.5±15.1 
37.3±16.2 
HBs Ag – During follow up, N (%) 93 (9.1) 
HBs Ab + During follow up, N (%) 57 (5.6) 
 
The age of the patients ranged from 4 to 83 years with the 
mean age of 30.82±11.27 years. The duration of follow-up 
was from 2 to 410 months and most patients were males 
(58.2%). All patients were Hepatitis B early-antigen (HBe 
Ag) negative and their ALT and AFP levels were normal in 
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the last test recorded at follow-up. Of the 93 patients with 
HBs Ag negative, 52 were antibody positive, and antibodies 
were formed in the blood of 5 patients despite the presence 
of positive antigen. Out of the 38 patients who took the drug, 
1 case was serocleared and 1 patient was seroconverted. The 
survival rate of HBs Ag positivity after 5, 10 and 15 years 
were 95.6, 89.4 and 80.7%, respectively (table 2, figure 1). 
 
Table 2. Survival rate of HBs Ag positivity during follow-up 
Follow-up duration (year) Survival ±SE 
5 95.6±0.7 
10 89.4±1.4 
15 80.7±2.5 
20 73.3±3.7 
25 66.8±5.5 
30 43.8±11.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cumulative survival rate of HBs Ag positivity 
during follow-up 
 
Seroconversion was not developed in 98, 93.5 and 84.9% 
of patients after 5, 10 and 15 years, respectively (table 3, 
figure 2). 
Table 3. Survival rate of HBs Ab negativity in CHB 
patients during follow-up 
 
Follow-up duration (year) Survival ±SE 
5 98±0.5 
10 93.5±1.1 
15 84.9±2.4 
20 79.5±3.5 
25 75.9±4.9 
30 69.6±7.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cumulative survival rate of HBs Ab negativity 
in CHB patients during follow-up 
 
Moreover, , Cox regression analysis indicated that age, 
gender and taking medication had no effect on HBs Ag 
seroclearance and seroconversion (tables 4 and 5). 
 
Table 4. Multivariable Cox regression model of the 
factors affecting HBs Ag negativity in patients with CHB 
Variables HR (95% CI) p-value 
Sex 1.27 (0.828-1.972) 0.269 
Age >30 1.261 (0.833-1.911) 0.273 
Drug 0.244 (0.34-1.256) 0.161 
 
Table 5. Multivariable Cox regression model of factors 
affecting HBs Ab positivity in patients with CHB 
Variables HR (95% CI) p-value 
Sex 1.431 (0.826-2.477) 0.201 
Age >30 1.329 (0.782-2.259) 0.293 
Drug 0.764 (0.186-3.142) 0.709 
 
 
Discussion 
In the present study cumulative incidence of HBs Ag 
seroclearance, HBs Ab seroconversion and possible factors 
affecting patients outcome were investigated. Totally, 
HBsAg seroclearnce and seroconversion was observed in 
9.1%and 5.6% of patients respectively. HBsAg seroclearance 
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and seroconversion are important events in the course of 
hepatitis B infection that can be good prognostic factors in 
disease outcome. The incidence rate of HBsAg seroclearnce 
is very low (1.6-1.8% per year), representing a rare event in 
the natural history of HBV infection..However, some studies 
have suggested that HBsAg seroclearance is more likely to 
occur due to aging and antiviral therapy in chronic hepatitis 
B patients (3, 9, 15). The results of current study were not in 
line with several investigations which considered age and 
antiviral therapy as factors that affect HBsAg seroclearance 
and seroconversion. 
Some risk factors for progression of chronic hepatitis B to 
seroclearance have been reported. Older age is a strong 
predictor of progression, but this is more likely due longer 
duration of disease rather than an independent risk factor. 
Age at entry has been identified as factor associated with 
increased HBsAg seroclearance (16-18). 
Another commonly associated risk factor is male sex 
although the exact mechanism is not clear (19). Spontaneous 
hepatitis B surface antigen (HBsAg) seroclearance is 
associated with a good prognosis in occurring during the 
inactive phase of chronic hepatitis B virus (HBV) infection 
Patients. is associated with excellent prognosis. HBsAg 
levels declined decreased to less than 200 and less than100 
IU/mL in 55% and 37% of the patients, respectively, at 5 
years before HBsAg seroclearance. The proportion part of 
patients reaching these levels of HBsAg increased to 100% 
and 98% at 1 year, respectively, and 81% and 64% at 3 
years, respectively, before HBsAg seroclearance.  
Itaru Ozeki et al. showed that during the mean follow-up 
period of 31 months, the HBsAg seroclearance rates 
determined by high-sensitivity HBsAg assays in discrepant 
cases were 20.8% at 1 year, 40.6% at 2, 51.3% at 3, 64.3% at 
4, and 74.5% at 5 years, respectively. The cumulative anti-
HBs positivity rates in discrepant cases were 12.7% at 
baseline, 17.2% at 1 year, and 38.8% at 3 years (15), which 
were significantly higher than those in the present study. Of 
course, the number of patients in their study was smaller 
than ours. 
In a study, Yen et al. illustrated that there was a 
significant relationship between HBs seroclearance with 
male gender and age over 60 years in patients. In their study, 
after treatment with interferon, 53 (26.4%) of 201 patients 
were HBs-Ag positive and among these patients, 15 patients 
developed anti HBs antibody. Moreover, 9.8 and 47.07% of 
patients were serocleared in 5 and 10 years, respectively, 
which is inconsistent with our study, indicating that 
treatment can be effective in seroclearing the patients (20). 
However, in our study, the duration and type of antiviral 
therapy was different. Like the present study, Fung et al.  
found that the HBs Ag seroclearance was 1.1%, 3.3%, 13.5% 
and 23.4% in 5, 10, 20 and 30 years after patients undergone 
HBe Ag seroclearance, respectively. In addition, in their 
study, the age had no effect on seroclearace, but patients who 
needed medication were serocleared later than those without 
medication. This may be because the patients who did not 
require medication were probably better in terms of status, 
number of viruses and blood biochemical factors. 
It was suggested that patients who were HBs Ag 
serocleared or HBs Ag seroconverted were less likely to 
develop HCC during follow-up. As the probability of viral 
rebound is negligible through HBs Ag seroclearance; 
therefore, it can be an appropriate endpoint for physicians to 
terminate (10). 
Zu et al. have demonstrated that if a person becomes 
infected with hepatitis B at an early age, it is more likely to 
be serocleared and seroconverted, which may be due to 
vaccination against hepatitis B at this age. Their study also 
illustrated that drug consumption increased the percentage of 
HBs Ag clearance from blood and antibody production, 
which disagrees with our results so this difference appears to 
be due to our retrospective study design and lack of 
monitoring of drug consumption (21). 
The study of Faisal et al. has indicated that higher the age 
of hepatitis in addition to the lower percentage of serocleared 
and seroconverted patients, the more likely the liver to 
develop fibrosis because in the older age, tissue regeneration 
is lower. Although the drug can be effective in HBs Ag 
seroconversion of patients, the type of drug is also effective. 
For example, the nocleosid analogs are unable to cure 
infection because they cannot remove cccDNA of the virus 
from the nucleus of hepatocytes (22). In our study, the drug 
had no significant effect on the course of the disease, which 
might be due to the type of drug being used. 
In the present study, there were some limitations. The first 
limitation was the retrospective study design; thus, the 
prospective studies are needed to follow-up patients more 
closely. Since HBs Ag seroclearance and HBs Ag 
seroconversion are rare, the low number of patients as well 
as patients taking medication was the second limitation of 
the study. 
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Despite the limitations of the study, the results have 
shown that during hepatitis B, the HBs Ag may be cleared in 
some patients, and even in some cases, the anti-HBs Ag 
antibodies may be formed. This is a rare occurrence, but it 
seems that the incidence of this may increase with time, age 
and drug consumption. Though there was no relationship 
between seroclearance with age and drug consumption in 
patients, further prospective studies with larger sample size 
may yield better results. 
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